Search clinical trials for: Hsp90 Inhibitor AT13387

Total 64023 results

National Cancer Institute (NCI)

Terminated

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Recurrent...

United States
National Cancer Institute (NCI)

Withdrawn

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal... and other conditions
National Cancer Institute (NCI)

Active, not recruiting

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditions

United States
Astex Pharmaceuticals, Inc.

Completed

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Metastatic Solid Tumors

United States
Esanex Inc.
National Cancer Institute (NCI)

Completed

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Lymphoma | Leukemia | Solid Tumor Malignancy | Lymphoid Malignancy (Lymphoma and CLL)

United States
Myrexis Inc.

Completed

Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditions

United States
National Cancer Institute (NCI)

Completed

AT13387 in Adults With Refractory Solid Tumors

Breast Cancer | Solid Tumors

United States
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer

Breast Cancer

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer

Colorectal Cancer

China
Dale Shepard, MD, PhD
National Cancer Institute (NCI)

Terminated

Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Philippines, United Kingdom
ARCIM Institute Academic Research in Complementary...

Recruiting

Efficacy of External Application of Rosemary Oil in Patients With Chemotherapy-Induced Peripheral Neuropathy: a Feasibility Study

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Germany
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Liver Cancer

China
Novartis Pharmaceuticals

Completed

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Advanced Solid Malignancies

France, Spain, Canada
National Cancer Institute (NCI)

Terminated

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Advanced Breast Carcinoma | Metastatic Breast Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.; Exelixis

Active, not recruiting

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma | Skin Cancer

United States
Novartis Pharmaceuticals

Terminated

Dose Escalation of HSP990 in Japan/Korea

Advanced Solid Tumors

Japan
Astex Pharmaceuticals, Inc.

Completed

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Non-small Cell Lung Cancer(NSCLC)

United States, Korea, Republic of, Spain, France, Canada
H. Lee Moffitt Cancer Center and Research Institute
Exelixis

Completed

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma

United States
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma (HSP70)

Hepatocellular Carcinoma

Taiwan
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Completed

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

Metastatic or Unresectable Solid Tumor Malignancy

United States
Emory University
Synta Pharmaceuticals Corp.

Terminated

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditions

United States
Astex Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Gastrointestinal Stromal Tumor (GIST)

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes... and other collaborators

Completed

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Recurrent Colorectal Carcinoma | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic... and other conditions

United States
Charite University, Berlin, Germany
Klinikum rechts der Isar, TU München, (TUM), Munich, Germany.

Recruiting

Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells (HSP70CTC)

Sarcoma | Prostate Cancer | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | Squamous Cell Carcinoma | Melanoma Stage IV

Germany
University of Connecticut

Completed

Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase

Leukemia,Myeloid, Chronic | Leukemia,Myeloid,Philadelphia-Positive

United States
Jonsson Comprehensive Cancer Center
Novartis; Translational Research in Oncology

Completed

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer

United States
UConn Health

Terminated

Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70

Breast Neoplasms

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Cervical Cancer | Precancerous Condition

United States
Northwestern University
Robert H. Lurie Cancer Center

Completed

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Adenocarcinoma of the Lung

United States
UMC Utrecht
Radboud University Medical Center; ZonMw: The Netherlands Organisation for... and other collaborators

Recruiting

Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis (TOLERANT)

Rheumatoid Arthritis

Netherlands
Technical University of Munich

Completed

Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

NSCLC Stage IIIA/B

Germany
Fox Chase Cancer Center
National Cancer Institute (NCI)

Terminated

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Astex Pharmaceuticals, Inc.

Completed

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Prostate Cancer

United States, United Kingdom, Spain, Canada
National Cancer Institute (NCI)

Active, not recruiting

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Laryngeal Squamous Cell Carcinoma AJCC... and other conditions

United States, Canada
QLT Inc.

Completed

Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

Retinitis Pigmentosa (RP)

Canada, Ireland
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Synta Pharmaceuticals Corp.; New York University...

Completed

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

Cervical Cancer | Precancerous Condition | HPV Disease | Human Papilomavirus

United States
St George's, University of London
European Union

Completed

Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine (TL01)

HIV Infections

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7 | Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm...

United States
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
Samsung Medical Center

Recruiting

Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention (PRESTIGE-AMI)

Heart Failure | Acute Myocardial Infarction

Korea, Republic of
Pfizer

Completed

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies (EUCHARIS)

Metastatic Breast Cancer

Spain, Belgium, Sweden, United Kingdom, Austria, Germany, Switzerland
Tianjin Medical University Cancer Institute and...

Recruiting

PD1 and PARP for Maintenance Therapy in NSLLC

Lung Cancer

China
Peking University
Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China

Recruiting

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (VISIONARY)

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Gastrointestinal Stromal Tumors | Neuroendocrine Tumors | Esophageal Squamous Cell Carcinoma | Biliary Tract Neoplasms | Unknown Primary Cancer | Digestive Cancer

China
Beijing Friendship Hospital
Changhai Hospital; Peking Union Medical College Hospital; Peking University Cancer...

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Locally Advanced Rectal Cancer

China

Search clinical trials for: Hsp90 Inhibitor AT13387

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations